Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Alnylam Hopes To Resume Fitusiran Dosing Quickly, Despite Unclear Cause Of Trial Death

Executive Summary

The RNAi pioneer voluntarily suspended dosing of the hemophilia candidate to consider trial protocol alterations after a patient receiving fitusiran in an open-label, Phase II trial died following a thrombosis event.

Advertisement

Related Content

Alnylam Plans Lumasiran Phase III As Market Landscape Gets Competitive
Deal Watch: As J.P. Morgan Waits For New Deals, Sanofi Takes Care Of Old Business
APOLLO Success Clears Alnylam For Lift-Off
Momentum Builds For Tomorrow's More Convenient Hemophilia Drugs
Alnylam's 'Day After' Revusiran Failure Bad, Maybe Not Catastrophic
Alnylam's Fitusiran Could Provide Comprehensive Hemophilia Therapy Option

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC099446

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel